Summary of Study ST001018

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000680. The data can be accessed directly via it's Project DOI: 10.21228/M8S684 This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST001018
Study TitleLarge Scale Profiling in Serum for Muscle Wasting in Cancer Cachexia (part-XII)
Study SummaryLarge Scale Profiling of muscle wasting in Cancer Cachexia. Serum samples from 10 control patients, 10 weight stable pancreatic cancer patients, and 10 pancreatic cancer patients with significant weight loss. Samples are divided evenly between males and females.
Mayo Clinic
Last NameGuttridge
First NameDenis
Address520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210
Submit Date2018-07-15
Analysis Type DetailLC-MS
Release Date2020-07-15
Release Version1
Denis Guttridge Denis Guttridge application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000680
Project DOI:doi: 10.21228/M8S684
Project Title:Mayo Pilot and Feasibility: Metabolomics of Muscle Wasting in Cancer Cachexia
Project Summary:Cachexia is a debilitating syndrome that results in severe, involuntary weight loss due to the depletion of skeletal muscle mass. This syndrome occurs in a majority of cancers and contributes to approximately one third of all cancer deaths. Currently, no effective therapy exists to combat this malignant disorder, and disappointing results from recent Phase III clinical trials indicate that a cachexia treatment is not likely to appear soon. Thus, it is clear that greater knowledge of the mechanisms driving muscle wasting in cachexia is needed in order to identify new therapeutic targets and stimulate new clinical trials. Our approach to gaining this knowledge has been to work with muscle biopsies from pancreatic cancer patients, since this population is highly prone to cachexia. We have also been expanding our studies beyond the classical mouse models of cancer cachexia in hopes of finding a new model that better recapitulates the human disease. We recently undertook RNA-Seq analysis comparing muscle biopsies from pancreatic cancer patients with and without cachexia, which has been exciting since this type of analysis has not yet been performed in patient samples. Preliminary results revealed that cachectic muscle was associated with alterations in metabolism. These data provide the rationale for performing metabolomics to ascertain whether specific metabolic pathways or metabolites can be identified as potential drivers of muscle wasting in cachexia or be used as biomarker of cachexia, which the field desperately needs. An additional need is a well-validated animal model of cancer cachexia that accurately reflects the human condition, which can be used to test mechanisms and pre-clinical compounds. We propose to perform these studies under the Mayo Clinic Metabolomics Resource Core Pilot and Feasibility Grant program to: 1) Identify metabolic alterations and biomarkers of pancreatic cancer-induced muscle wasting; and 2) Identify a suitable mouse model that recapitulates the metabolic imbalance of muscles from pancreatic cancer cachexia patients. By performing these studies, we will accelerate our understanding of the underlying causes of muscle wasting, which should translate to improving the current pipeline of anticachexia therapies.
Institute:Mayo Clinic
Last Name:Guttridge
First Name:Denis
Address:520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210


Subject ID:SU001057
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606


Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Groups Gender
SA063822philic-30may17-007Control Female
SA063823philic-30may17-004Control Female
SA063824philic-30may17-009Control Female
SA063825philic-30may17-018Control Female
SA063826nC18-31may17-018Control Female
SA063827philic-30may17-003Control Female
SA063828pC18-30may17-009Control Female
SA063829pC18-30may17-003Control Female
SA063830pC18-30may17-004Control Female
SA063831pC18-30may17-007Control Female
SA063832nhilic-31may17-018Control Female
SA063833nhilic-31may17-007Control Female
SA063834nhilic-31may17-009Control Female
SA063835nC18-31may17-009Control Female
SA063836nC18-31may17-007Control Female
SA063837nC18-31may17-004Control Female
SA063838nC18-31may17-003Control Female
SA063839nhilic-31may17-003Control Female
SA063840pC18-30may17-018Control Female
SA063841nhilic-31may17-004Control Female
SA063842nhilic-31may17-020Control Male
SA063843pC18-30may17-015Control Male
SA063844pC18-30may17-027Control Male
SA063845nhilic-31may17-010Control Male
SA063846pC18-30may17-020Control Male
SA063847nhilic-31may17-015Control Male
SA063848nhilic-31may17-002Control Male
SA063849pC18-30may17-010Control Male
SA063850pC18-30may17-002Control Male
SA063851nC18-31may17-027Control Male
SA063852nC18-31may17-015Control Male
SA063853philic-30may17-010Control Male
SA063854philic-30may17-020Control Male
SA063855nC18-31may17-010Control Male
SA063856nC18-31may17-002Control Male
SA063857philic-30may17-027Control Male
SA063858nC18-31may17-020Control Male
SA063859philic-30may17-015Control Male
SA063860nhilic-31may17-027Control Male
SA063861philic-30may17-002Control Male
SA063862philic-30may17-029Weight Losing Female
SA063863nC18-31may17-001Weight Losing Female
SA063864nhilic-31may17-026Weight Losing Female
SA063865pC18-30may17-029Weight Losing Female
SA063866nhilic-31may17-021Weight Losing Female
SA063867philic-30may17-022Weight Losing Female
SA063868nhilic-31may17-022Weight Losing Female
SA063869philic-30may17-001Weight Losing Female
SA063870pC18-30may17-026Weight Losing Female
SA063871nhilic-31may17-029Weight Losing Female
SA063872philic-30may17-021Weight Losing Female
SA063873philic-30may17-026Weight Losing Female
SA063874nhilic-31may17-001Weight Losing Female
SA063875pC18-30may17-021Weight Losing Female
SA063876nC18-31may17-022Weight Losing Female
SA063877nC18-31may17-029Weight Losing Female
SA063878nC18-31may17-026Weight Losing Female
SA063879pC18-30may17-001Weight Losing Female
SA063880pC18-30may17-022Weight Losing Female
SA063881nC18-31may17-021Weight Losing Female
SA063882nhilic-31may17-030Weight Losing Male
SA063883nhilic-31may17-014Weight Losing Male
SA063884pC18-30may17-005Weight Losing Male
SA063885nC18-31may17-030Weight Losing Male
SA063886philic-30may17-006Weight Losing Male
SA063887philic-30may17-013Weight Losing Male
SA063888philic-30may17-014Weight Losing Male
SA063889nC18-31may17-014Weight Losing Male
SA063890nhilic-31may17-013Weight Losing Male
SA063891philic-30may17-005Weight Losing Male
SA063892nC18-31may17-013Weight Losing Male
SA063893pC18-30may17-006Weight Losing Male
SA063894nhilic-31may17-006Weight Losing Male
SA063895nC18-31may17-006Weight Losing Male
SA063896nhilic-31may17-005Weight Losing Male
SA063897pC18-30may17-030Weight Losing Male
SA063898nC18-31may17-005Weight Losing Male
SA063899philic-30may17-030Weight Losing Male
SA063900pC18-30may17-013Weight Losing Male
SA063901pC18-30may17-014Weight Losing Male
SA063902nhilic-31may17-016Weight Stable Female
SA063903nC18-31may17-019Weight Stable Female
SA063904nhilic-31may17-017Weight Stable Female
SA063905pC18-30may17-019Weight Stable Female
SA063906pC18-30may17-017Weight Stable Female
SA063907philic-30may17-019Weight Stable Female
SA063908nC18-31may17-016Weight Stable Female
SA063909philic-30may17-016Weight Stable Female
SA063910nC18-31may17-017Weight Stable Female
SA063911pC18-30may17-024Weight Stable Female
SA063912philic-30may17-025Weight Stable Female
SA063913pC18-30may17-016Weight Stable Female
SA063914philic-30may17-024Weight Stable Female
SA063915pC18-30may17-025Weight Stable Female
SA063916philic-30may17-017Weight Stable Female
SA063917nhilic-31may17-024Weight Stable Female
SA063918nhilic-31may17-019Weight Stable Female
SA063919nC18-31may17-024Weight Stable Female
SA063920nC18-31may17-025Weight Stable Female
SA063921nhilic-31may17-025Weight Stable Female
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 120


Collection ID:CO001051
Collection Summary:Tissue and blood donated from Cancer Cachexia Program at Ohio State University
Sample Type:Blood (serum)


Treatment ID:TR001071
Treatment Summary:Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, with the most notable symptom being unintentional weight loss. Cachectic patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss and its associated weakness contributing to the morbidity and mortality of these patients. Despite three decades of research into mechanisms driving muscle wasting due to cancer, to date, an approved pharmacological therapy to prevent or treat cancer cachexia is still lacking. Our laboratory focuses on cancer cachexia in patients with pancreatic cancer, as up to 85% of these patients experience weight loss. Cachexia often occurs early in the progression of pancreatic cancer, making clear that cachexia in these patients is not simply a result of end-stage disease. Further, with perhaps more than ΒΌ of all pancreatic cancer deaths resulting from muscle weakness as opposed to tumor burden, cachexia also significantly contributes to mortality due to pancreatic cancer. Because little progress has been made in improving treatment outcomes, addressing cancer-induced muscle wasting is perhaps the best strategy to prolong pancreatic cancer patient survival and increase patient quality of life. In an effort to better understand the mechanisms driving pancreatic cancer-induced muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing attempted resection for pancreatic cancer or other abdominal surgeries have donated muscle and blood to our bank. A unique aspect of our tissue bank is our focus on patients eligible for resection. In contrast to other studies using patients with late-stage disease, our patients are not end-stage, as they are considered healthy enough to undergo a major operation.

Sample Preparation:

Sampleprep ID:SP001064
Sampleprep Summary:large scale profiling using serum

Combined analysis:

Analysis ID AN001663 AN001664 AN001665 AN001666
Analysis type MS MS MS MS
Chromatography type HILIC HILIC Reversed phase Reversed phase
Chromatography system Agilent 1290 Infinity Agilent 1290 Infinity Agilent 1290 Infinity Agilent 1290 Infinity
Column Waters Acquity BEH Amide (150 x 2.1mm,1.7um) Waters Acquity BEH Amide (150 x 2.1mm,1.7um) Waters Acquity HSS C18 (150 x 2.1mm,1.8um) Waters Acquity HSS C18 (150 x 2.1mm,1.8um)
MS instrument type QTOF QTOF QTOF QTOF
MS instrument name Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF Agilent 6550 QTOF
Units intensity intensity intensity intensity


Chromatography ID:CH001172
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity BEH Amide (150 x 2.1mm,1.7um)
Chromatography Type:HILIC
Chromatography ID:CH001173
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity HSS C18 (150 x 2.1mm,1.8um)
Chromatography Type:Reversed phase


MS ID:MS001538
Analysis ID:AN001663
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS ID:MS001539
Analysis ID:AN001664
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS ID:MS001540
Analysis ID:AN001665
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF
MS ID:MS001541
Analysis ID:AN001666
Instrument Name:Agilent 6550 QTOF
Instrument Type:QTOF